open-targets
Connecting AI to biology: Model Context Protocol
New data initiative accelerates discovery and personalised care for mental health conditions
New platform integrates gene perturbation data
BioChatter: making large language models accessible for biomedical research
Cancer drug resistance causes and categories identified
Why clinical trials stop: the role of genetics
We are EMBL: Melanie Schneider on changing career trajectory
MSD joins the Open Targets consortium
Deciphering the data deluge: how large language models are transforming scientific data curation
Welcome: David Hulcoop
EMBL-EBI’s new building set to support data growth and innovative partnerships
David Hulcoop appointed as Open Targets Director
ProtVar: understanding missense variation in humans
A human interactome to prioritise drug discovery
Machine learning to identify and prioritise drug targets
Open Targets consortium welcomes Genentech as newest member
Pfizer joins the Open Targets consortium
The human genome, data sharing, and drug discovery: a career profile with Ian Dunham
The PROTACtable genome – a new route to drug discovery
eQTL Catalogue – a new resource for gene expression and splicing QTLs
A machine learning approach to identify functional human phosphosites
CRISPR offers new insights into critical cancer changes
Prioritising cancer drug targets using CRISPR
Ian Dunham appointed as Open Targets Director
Sanofi joins Open Targets
Celgene joins Open Targets
Takeda joins drug target discovery initiative
A better way to find drug targets
UX design for the life sciences: myths and realities
